Loading…
Century Therapeutics, Inc. is projected to rise to $2.46 by 2027, a +9% move from its current price of $2.25. IPSC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.18 | $2.25 | $2.32 | +0.04% |
| Jul 13 | $2.16 | $2.25 | $2.35 | +0.09% |
| Jul 14 | $2.14 | $2.25 | $2.38 | +0.13% |
| Jul 15 | $2.12 | $2.25 | $2.40 | +0.18% |
| Jul 16 | $2.11 | $2.26 | $2.41 | +0.22% |
| Jul 17 | $2.09 | $2.26 | $2.43 | +0.27% |
| Jul 18 | $2.08 | $2.26 | $2.45 | +0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.08 | $2.26 | $2.45 | +0.31% |
| Week 2 | $2.02 | $2.26 | $2.54 | +0.63% |
| Week 3 | $1.97 | $2.27 | $2.61 | +0.94% |
| Week 4 | $1.94 | $2.28 | $2.68 | +1.26% |
| Week 5 | $1.91 | $2.29 | $2.74 | +1.58% |
| Week 6 | $1.88 | $2.29 | $2.79 | +1.90% |
| Week 7 | $1.86 | $2.30 | $2.85 | +2.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania, and it is categorized within Healthcare.
Century Therapeutics is focused on advancing allogeneic cell therapies with multiple candidates in its pipeline, including CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0, and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits designed for CD19 and autoimmune diseases. The description positions Century Therapeutics as a player in the biotechnology space with a portfolio of engineered cell therapies.
The stock trades under the IPSC symbol and is categorized in Healthcare, reflecting its listing and sector alignment while pursuing its clinical development programs."
IPSC is the equity for Century Therapeutics, Inc., a biotechnology company focused on allogeneic cell therapies. The stock has a current price of $2.41 and a market capitalization of $434.66M, with a rank of 3160 among listed assets. The current price sits within a context of technical support and resistance levels that frame a near-term price path.
From a forecasting perspective, the model envisions a multi-year uptrend with the 2026 average price at $2.41 and a path higher to $3.83 by 2030, eventually reaching $21.91 by 2050, implying substantial longer-term upside. The forecast shows rising average prices and sizable ROI potential by 2031 and beyond, suggesting a bullish longer-term outlook despite near-term uncertainty.
Short-term and multi-year projections should be viewed as estimates, not guarantees. The intended takeaway is that IPSC could trend higher over a horizon extending into 2050, with cumulative upside reflected in higher average prices and ROI figures reflected in the forecast."
A major floor 16.6% below — a decisive break under it would weaken the trend.
The nearest floor, 8.0% below — buyers have tended to step in here.
The nearest ceiling, 8.9% above — a clean break opens room to run.
A major ceiling 30.7% above — clearing it would confirm fresh momentum.
Key IPSC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of IPSC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.34 | Sell | $2.33 | Sell |
| MA 10 | $2.37 | Sell | $2.34 | Sell |
| MA 20 | $2.33 | Sell | $2.33 | Sell |
| MA 50 | $2.29 | Sell | $2.29 | Sell |
| MA 100 | $2.30 | Sell | $2.15 | Buy |
| MA 200 | $1.64 | Buy | $1.83 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.45 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -78.46 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -6.64 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.19 | Buy |
| Awesome (5,34) | 0.05 | Buy |
| Ultimate (7,14,28) | 37.71 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 2.31 | Sell |
| ADX (14) | 7.88 | Neutral |
| ATR (14) | 0.07 | Info |
The 30-day technical picture shows a bullish tilt with an RSI14 of 60, indicating momentum toward the upside. The stock trades above the 50-day moving average of $2.29 and well above the 200-day moving average of $1.53, supporting a constructive intermediate-term view.
Nearby levels to watch include a support at $2.07 and a resistance at $2.45. Over the last 30 days, the price range has moved from a low of $1.93 to a high of $3.00, highlighting the momentum and volatility within a defined band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.90 | $2.25 | $2.97 | 0% | Neutral | |
| $1.94 | $2.46 | $3.32 | +9% | Neutral | |
| $2.02 | $2.65 | $3.72 | +18% | Neutral | |
| $2.02 | $2.71 | $3.93 | +21% | Bullish | |
| $2.29 | $3.16 | $4.70 | +40% | Bullish | |
| $2.73 | $3.84 | $5.85 | +71% | Bullish | |
| $2.97 | $4.26 | $6.62 | +89% | Bullish | |
| $3.09 | $4.52 | $7.16 | +101% | Bullish | |
| $2.85 | $4.23 | $6.83 | +88% | Bullish | |
| $2.99 | $4.53 | $7.42 | +101% | Bullish | |
| $4.13 | $6.76 | $11.84 | +201% | Bullish | |
| $8.01 | $15.02 | $28.97 | +568% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.90 | $2.25 | $2.67 | +0.00% |
| August 2026 | $1.93 | $2.29 | $2.79 | +1.74% |
| September 2026 | $1.96 | $2.34 | $2.89 | +2.38% |
| October 2026 | $1.91 | $2.29 | $2.85 | -2.32% |
| November 2026 | $1.87 | $2.26 | $2.85 | -1.09% |
| December 2026 | $1.93 | $2.35 | $2.97 | +3.57% |
Click any year to see its month-by-month IPSC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Century Therapeutics, Inc.'s 2026 outlook centres on $2.25, within a $0.90 to $2.97 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, IPSC could reach as high as $3.32, with a base case around $2.46 and support toward $1.94 — roughly +9% from $2.25. A consolidation phase looks the most probable path here.
Expect IPSC to range from $2.02 to $3.72 through 2028. The $2.65 average target implies a +18% move from current prices. That is up +8% on the projected 2027 average. Price action looks broadly range-bound.
The IPSC price prediction for 2029 points to an average of $2.71 (low $2.02, high $3.93) — a potential gain of +21% on today's $2.25. Buyers look set to stay in control over this stretch.
In 2030, IPSC is projected to trade between $2.29 and $4.70, averaging $3.16 — a potential gain of +40% from today's $2.25. That is up +16% on the projected 2029 average. Momentum favours further upside here.
Century Therapeutics, Inc.'s 2031 outlook centres on $3.84, within a $2.73 to $5.85 range. That is up +22% on the projected 2030 average. That marks a +71% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, IPSC could reach as high as $6.62, with a base case around $4.26 and support toward $2.97 — roughly +89% from $2.25. Momentum favours further upside here.
Expect IPSC to range from $3.09 to $7.16 through 2033. The $4.52 average target implies a +101% move from current prices. That is up +6% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The IPSC price prediction for 2034 points to an average of $4.23 (low $2.85, high $6.83) — a potential gain of +88% on today's $2.25. Momentum favours further upside here.
In 2035, IPSC is projected to trade between $2.99 and $7.42, averaging $4.53 — a potential gain of +101% from today's $2.25. That is up +7% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Century Therapeutics, Inc.'s 2040 outlook centres on $6.76, within a $4.13 to $11.84 range. That is up +49% on the projected 2035 average. That marks a +201% change versus current levels. Momentum favours further upside here.
By 2050, IPSC could reach as high as $28.97, with a base case around $15.02 and support toward $8.01 — roughly +568% from $2.25. Buyers look set to stay in control over this stretch.
Investing $1,000 in IPSC today (≈ 444.444444 IPSC) could be worth
$6,675.69
+$5,675.69 (+568%) by 2050 · US Dollar
Based on the average projected IPSC price of $15.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in IPSCwould be worth at today's price.
$1,000 invested in IPSC on Jul 10, 2025 (≈ 1,618.123054 IPSC) would be worth
$3,640.78
+$2,640.78 (+264.1%) today · 3.64× · US Dollar
Based on a IPSC entry price of $0.618 vs. today's $2.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.43 | $925.93 | -7.4% |
| 1 month ago | $2.12 | $1,061.32 | +6.1% |
| 3 months ago | $2.25 | $1,000 | +0.0% |
| 6 months ago | $2.04 | $1,102.94 | +10.3% |
| 1 year ago | $0.618 | $3,640.78 | +264.1% |
| All time (5.0y) ago | $27.25 | $82.57 | -91.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our IPSC forecast.
Our base-case forecast reaches $4.50 around 2033.
Implied market cap at $4.50: $811.6M
The multi-year forecast paints a distinctly bullish trajectory for IPSC, with meaningful upside through the next decades. In 2030 the average price is projected to be $3.83, reflecting a 58.9% ROI, and the sentiment remains BULLISH. By 2040, the average is forecast at $9.32 with a 286.7% ROI, maintaining a bullish stance.
By 2050 the model envisions an average price of $21.91 and an ROI of 809.3%, with sentiment remaining BULLISH. Earlier years show a gradual climb from 2026’s average of $2.41 to 2029’s $3.21 before accelerating in the 2030s and beyond. These are estimates, and actual outcomes can differ due to market conditions and company-specific developments.
Tap a question to reveal the answer.
In 2030, the forecast shows an average price of $3.83 with a range from $2.73 to $5.83 and an approximate ROI of 58.9%, with a bullish sentiment.
The forecast depicts rising average prices over time, from $2.41 in 2026 to $21.91 in 2050, with ROI expanding to 809.3% by 2050 and bullish sentiment in later years; however, these are estimates and not guarantees.
According to the forecast, the 2050 max is $43.89, so reaching $50 is not indicated by these projections.
The current price is $2.41 and the market capitalization is $434.66M.
For 2040, the average price is forecast at $9.32 with a min of $5.46 and a max of $16.86, and the ROI is forecast at 286.7% with bullish sentiment.
Century Therapeutics, Inc. Community Discussion
0Share your Century Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.